(IHE) iShares U.S. Pharmaceuticals - Ratings and Ratios
Pharmaceuticals, Vaccines, Prescription Drugs, Over-The-Counter Drugs
Dividends
| Dividend Yield | 1.35% |
| Yield on Cost 5y | 2.10% |
| Yield CAGR 5y | -14.55% |
| Payout Consistency | 89.4% |
| Payout Ratio | - |
| Risk via 10d forecast | |
|---|---|
| Volatility | 15.8% |
| Value at Risk 5%th | 26.0% |
| Relative Tail Risk | 0.28% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.89 |
| Alpha | 12.89 |
| CAGR/Max DD | 0.78 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.490 |
| Beta | 0.504 |
| Beta Downside | 0.582 |
| Drawdowns 3y | |
|---|---|
| Max DD | 15.92% |
| Mean DD | 4.44% |
| Median DD | 3.82% |
Description: IHE iShares U.S. Pharmaceuticals October 23, 2025
The iShares U.S. Pharmaceuticals ETF (NYSE ARCA:IHE) tracks an index of U.S. companies that develop, manufacture, or market prescription drugs, over-the-counter medicines, and vaccines. The fund is required to hold at least 80 % of its net assets in the underlying securities and may allocate up to 20 % to derivatives, cash, or cash equivalents; it is classified as a non-diversified ETF.
Key quantitative points (as of the most recent filing) include an expense ratio of 0.43 %, total assets of roughly $1.2 billion, and a top-10 holding concentration of about 30 % of assets, dominated by large caps such as Pfizer, Johnson & Johnson, and Merck. The sector’s growth outlook is driven by an aging U.S. population (projected to increase the 65+ cohort by ~10 % over the next decade), accelerating demand for specialty biologics, and a regulatory environment that is gradually shifting toward faster approvals for breakthrough therapies, though pricing pressure from Medicare and pharmacy benefit managers remains a headwind.
For a deeper, data-rich analysis of IHE’s risk-adjusted performance and how its exposure aligns with macro-level health-care trends, you might explore the ValueRay platform.
What is the price of IHE shares?
Over the past week, the price has changed by -1.32%, over one month by +9.59%, over three months by +16.72% and over the past year by +23.29%.
Is IHE a buy, sell or hold?
What are the forecasts/targets for the IHE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 92.6 | 11.4% |
IHE Fundamental Data Overview December 02, 2025
Beta = 0.65
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 802.1m USD (802.1m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 802.1m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 802.1m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 7.87% (E(802.1m)/V(802.1m) * Re(7.87%) + (debt-free company))
Discount Rate = 7.87% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for IHE ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle